Last reviewed · How we verify

Lambda Therapeutic Research Ltd. — Portfolio Competitive Intelligence Brief

Lambda Therapeutic Research Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Denosumab-Ref Denosumab-Ref phase 3 RANKL inhibitor (monoclonal antibody) RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) Oncology, Bone Metabolism

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 1 shared drug class
  2. GlaxoSmithKline · 1 shared drug class
  3. Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 shared drug class
  4. Luye Pharma Group Ltd. · 1 shared drug class
  5. Prince of Wales Hospital, Shatin, Hong Kong · 1 shared drug class
  6. Seoul National University Bundang Hospital · 1 shared drug class
  7. Swiss Cancer Institute · 1 shared drug class
  8. University of Alabama at Birmingham · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lambda Therapeutic Research Ltd.:

Cite this brief

Drug Landscape (2026). Lambda Therapeutic Research Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lambda-therapeutic-research-ltd. Accessed 2026-06-10.

Related